Effect of a toggle switch mutation in TM6 of the human adenosine A 3 receptor on Gi protein-dependent signalling and Gi-independent receptor internalization

British Journal of Pharmacology

Volumn 171, Issue 16, 2014, Pages 3827-3844

  Stoddart, Leigh A ^a   Kellam, Barrie ^b   Briddon, Stephen J ^a   Hill, Stephen J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 HEXYNYL) N METHYLADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; BETA ARRESTIN 2; CYCLIC AMP; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; PHENYLALANINE; TRITIUM; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; 2-HEXYN-1-YL-N(6)-METHYLADENOSINE; ADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; BIOLOGICAL MONITORING; CELL MEMBRANE; CELL STRAIN CHO K1; CHO CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMAGE ANALYSIS; INTERNALIZATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPORTER GENE; SECOND MESSENGER; SIGNAL TRANSDUCTION; TRANSMEMBRANE DOMAIN 6; ANALOGS AND DERIVATIVES; ANIMAL; CRICETULUS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ADENOSINE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANIMALS; ARRESTINS; CHO CELLS; CRICETULUS; CYCLIC AMP; GTP-BINDING PROTEINS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PROTEIN STRUCTURE, TERTIARY; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION;

EID: 84905028134     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12739     Document Type: Article

References (50)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et-al. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci 11406-11411.
3. Baker JG, Hall IP, Hill SJ, (2003). Agonist and inverse agonist actions of beta-blockers at the human beta(2)-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64: 1357-1369.
4. Baker JG, Hall IP, Hill SJ, (2002). Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br J Pharmacol 137: 400-408.
5. Baker JG, Hall IP, Hill SJ, (2004). Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol 65: 986-998.
6. Boutin A, Allen MD, Neumann S, Gershengorn MC, (2012). Persistent signaling by thyrotropin-releasing hormone receptors correlates with G-protein and receptor levels. FASEB J 26: 3473-3482.
7. Deupi X, Standfuss J, (2011). Structural insights into agonist-induced activation of G protein-coupled receptors. Curr Opin Struct Biol 21: 541-551.
8. Donaldson J, Brown AM, Hill SJ, (1988). Influence of rolipram on the cyclic 3′,5′-adenosine-monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem Pharmacol 37: 715-723.
9. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG, (1996). Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274: 768-770.
10. Feinstein TN, Wehbi VL, Ardura JA, Wheeler DS, Ferrandon S, Gardella TJ, et-al. (2011). Retromer terminates the generation of cAMP by internalized PTH receptors. Nat Chem Biol 7: 278-284.
11. Ferguson G, Watterson KR, Palmer TM, (2002). Subtype-specific regulation of receptor internalization and recycling by the carboxyl-terminal domains of the human A(1) and rat A(3) adenosine receptors: consequences for agonist-stimulated translocation of arrestin3. Biochem 41: 14748-14761.
12. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE, (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63: 1-34.
13. Gaborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, Hunyady L, (2003). The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinol 144: 2220-2228.
14. Gao ZG, Jacobson KA, (2008). Translocation of arrestin induced by human A3 adenosine receptor ligands in an engineered cell line: comparison with G Protein-dependent pathways. Pharmacol Res 57: 303-311.
15. Gao ZG, Chen A, Barak D, Kim SK, Muller CE, Jacobson KA, (2002). Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A(3) adenosine receptor. J Biol Chem 277: 19056-19063.
16. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, et-al. (2006). Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated eRK1/2 activation. J Biol Chem 281: 10856-10864.
17. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK, (1997). Agonists induce conformational changes in transmembrane domains III and VI of the beta(2) adrenoceptor. EMBO J 16: 6737-6747.
18. Hoffmann C, Ziegler N, Reiner S, Krasel C, Lohse MJ, (2008). Agonist-selective, receptor-specific interaction of human P2Y receptors with β-arrestin-1 and -2. J Biol Chem 283: 30933-30941.
19. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW, (2003). High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 17: 2201-2210.
20. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, et-al. (2010). A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J Biol Chem 285: 3973-3985.
21. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, et-al. (2013). Conformational biosensors reveal GPCR signalling from endosomes. Nature 495: 534-538.
22. Katritch V, Cherezov V, Stevens RC, (2013). Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53: 531-556.
23. Kenakin TP, (2012). Biased signaling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165: 1659-1669.
24. Kilpatrick LE, Briddon SJ, Hill SJ, Holliday ND, (2010). Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation. Br J Pharmacol 160: 892-906.
25. Lefkowitz RJ, Shenoy SK, (2005). Transduction of receptor signals by beta-arrestins. Science 308: 512-517.
26. Marie J, Richard E, Pruneau D, Paquet JL, Siatka C, Larguier R, et-al. (2001). Control of conformational equilibria in the human B2 bradykinin receptor: modeling of nonpeptidic ligand action and comparison to the rhodopsin structure. J Biol Chem 276: 41100-41111.
27. Morell M, Espargaro A, Aviles FX, Ventura S, (2007). Detection of transient protein-protein interactions by bimolecular fluorescence complementation: the Abl-SH3 case. Proteomics 7: 1023-1036.
28. Moukhametzianov R, Warne T, Edwards PC, Serrano-Vega MJ, Leslie AGW, Tate CG, et-al. (2011). Two distinct conformations of helix 6 observed in antagonist-bound structures of a β1-adrenergic receptor. Proc Natl Acad Sci 108: 8228-8232.
29. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K, (2009). Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5: 428-434.
30. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW, (2009). Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 249-259.
31. Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M, et-al. (2009). Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol Pharmacol 75: 982-990.
32. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, et-al. (2011). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469: 175-180.
33. Ridge KD, Bhattacharya S, Nakayama TA, Khorana HG, (1992). Light stable rhodopsin. II. An opsin mutant (TRP-265-PHE) and a retinal analogue with a nonisomerizable II-cis configuration form a photostable chromophore. J Biol Chem 267: 6770-6775.
34. Rose RH, Briddon SJ, Holliday ND, (2010). Bimolecular fluorescence complementation: lighting up seven transmembrane domain receptor signalling networks. Br J Pharmacol 159: 738-750.
35. Schulte G, Fredholm BB, (2002). Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 62: 1137-1146.
36. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE, (2006). Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46: 481-519.
37. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA, (2002). β2 adrenergic receptor activation. J Biol Chem 277: 40989-40996.
38. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ, (2008). Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci 105: 9988-9993.
39. Stoddart LA, Vernall AJ, Denman JL, Briddon SJ, Kellam B, Hill SJ, (2012). Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. Chem Biol 19: 1105-1115.
40. Tate CG, Schertler GFX, (2009). Engineering G protein-coupled receptors to facilitate their structure determination. Curr Opin Struct Biol 19: 386-395.
41. Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, et-al. (2002). A(3) adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol 62: 1373-1384.
42. Venkatakrishnan AJ, Deupi X, Lenon G, Tate CG, Schertler GF, Babu MM, (2013). Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
43. Watson S-J, Brown AJH, Holliday ND, (2012). Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol 81: 631-642.
44. Wei HJ, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et-al. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci 100: 10782-10787.
45. Werthmann RC, Volpe S, Lohse MJ, Calebiro D, (2012). Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J 26: 2043-2048.
46. Wess J, Nanavati S, Vogel Z, Maggio R, (1993). Functional role of proline and tryptophan residues highly conserved amount G protein-coupled receptors studied by mutational analysis of the M3 muscarinic receptor. EMBO J 12: 331-338.
47. Whalen EJ, Rajagopal S, Lefkowitz RJ, (2011). Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 17: 126-139.
48. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et-al. (2007). A unique mechanism of βblocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci 104: 16657-16662.
49. Xu F, Wu HX, Katritch V, Han GW, Jacobson KA, Gao ZG, et-al. (2011). Structure of an agonist-bound human A(2A) adenosine receptor. Science 332: 322-327.
50. Yao XJ, Parnot C, Deupi X, Ratnala VRP, Swaminath G, Farrens D, et-al. (2006). Coupling ligand structure to specific conformational switches in the beta(2)-adrenoceptor. Nat Chem Biol 2: 417-422.